# A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

> **NCT04956263** · PHASE2 · COMPLETED · sponsor: **Youngene Therapeutics Inc., Ltd.** · enrollment: 19 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1
- Type1diabetes
- Diabetes Mellitus

## Interventions

- **DRUG:** YG1699
- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT04956263
- **Lead sponsor:** Youngene Therapeutics Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-17
- **Primary completion:** 2022-02-02
- **Final completion:** 2022-07-19
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2022-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04956263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04956263, "A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04956263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*